发明授权
- 专利标题: Structurally modified peptides that are resistant to peptidase degradation
- 专利标题(中): 对肽酶降解有抗性的结构修饰的肽
-
申请号: US795733申请日: 1997-02-05
-
公开(公告)号: US6087441A公开(公告)日: 2000-07-11
- 发明人: Jean Edouard Gairin , Maha Ayyoub , Benoit Van Den Eynde , Honore Mazarguil , Bernard Monsarrat
- 申请人: Jean Edouard Gairin , Maha Ayyoub , Benoit Van Den Eynde , Honore Mazarguil , Bernard Monsarrat
- 申请人地址: NY New York
- 专利权人: Ludwig Institute for Cancer Research
- 当前专利权人: Ludwig Institute for Cancer Research
- 当前专利权人地址: NY New York
- 主分类号: A61K38/00
- IPC分类号: A61K38/00 ; A61K39/00 ; C07K14/705 ; A61K38/04 ; A61K39/395 ; C07K7/06 ; C07K16/00
摘要:
Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.
公开/授权文献
- US4137122A Method of manufacturing a semiconductor device 公开/授权日:1979-01-30
信息查询
IPC分类: